{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:25:01Z","timestamp":1790130301895,"version":"4.0.1"},"reference-count":149,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001774","name":"The University of Sydney","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Med"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40290-026-00617-x","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T12:13:59Z","timestamp":1784031239000},"page":"335-349","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Animal Models for Drug Discovery in Schizophrenia: A Critical View from a Clinical Perspective"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5878-4149","authenticated-orcid":false,"given":"Inga","family":"Dammann-Bawadkji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8163-195X","authenticated-orcid":false,"given":"F. Markus","family":"Leweke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3559-1846","authenticated-orcid":false,"given":"Cathrin","family":"Rohleder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"617_CR1","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/archpsyc.1982.04290070025006","volume":"39","author":"NC Andreasen","year":"1982","unstructured":"Andreasen NC, Olsen S. Negative v positive schizophrenia: definition and validation. Arch Gen Psychiatry. 1982;39:789\u201394. https:\/\/doi.org\/10.1001\/archpsyc.1982.04290070025006.","journal-title":"Arch Gen Psychiatry"},{"key":"617_CR2","doi-asserted-by":"publisher","unstructured":"American Psychiatric Association, DSM-5 Task Force. Diagnostic and statistical manual of mental disorders: DSM-5TM, 5th ed. American Psychiatric Publishing, Inc.; 2013. https:\/\/doi.org\/10.1176\/appi.books.9780890425596.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"617_CR3","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/s0140-6736(15)01121-6","volume":"388","author":"MJ Owen","year":"2016","unstructured":"Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet. 2016;388:86\u201397. https:\/\/doi.org\/10.1016\/s0140-6736(15)01121-6.","journal-title":"Lancet"},{"issue":"Suppl 9","key":"617_CR4","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.5694\/mja2.50383","volume":"211","author":"IB Hickie","year":"2019","unstructured":"Hickie IB, Scott EM, Cross SP, Iorfino F, Davenport TA, Guastella AJ, et al. Right care, first time: a highly personalised and measurement-based care model to manage youth mental health. MJA. 2019;211(Suppl 9):S3-46. https:\/\/doi.org\/10.5694\/mja2.50383.","journal-title":"MJA"},{"key":"617_CR5","doi-asserted-by":"publisher","unstructured":"Scott EM, Carpenter JS, Iorfino F, Cross SPM, Hermens DF, White D, et al. Chapter 5\u2014early intervention, prevention, and prediction in mood disorders: tracking multidimensional outcomes in young people presenting for mental health care. San Diego: Academic Press; 2020. p. 39\u201362. https:\/\/doi.org\/10.1016\/b978-0-12-813176-3.00005-5.","DOI":"10.1016\/b978-0-12-813176-3.00005-5"},{"key":"617_CR6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41572-025-00667-6","volume":"11","author":"S Leucht","year":"2025","unstructured":"Leucht S, Siafis S, McGrath JJ, McGorry P, Howes OD, Tamminga C, et al. Schizophrenia. Nat Rev Dis Prim. 2025;11:83. https:\/\/doi.org\/10.1038\/s41572-025-00667-6.","journal-title":"Nat Rev Dis Prim"},{"key":"617_CR7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/nature09552","volume":"468","author":"TR Insel","year":"2010","unstructured":"Insel TR. Rethinking schizophrenia. Nature. 2010;468:187\u201393. https:\/\/doi.org\/10.1038\/nature09552.","journal-title":"Nature"},{"key":"617_CR8","doi-asserted-by":"publisher","unstructured":"National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Forum on Neuroscience and Nervous System Disorders. In: Stroud C, Norris SMP, Bain L, editors. From molecular insights to patient stratification for neurological and psychiatric disorders. Washington (DC): National Academies Press (US); 2022. https:\/\/doi.org\/10.17226\/26468.","DOI":"10.17226\/26468"},{"key":"617_CR9","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/j.1600-0773.1963.tb01730.x","volume":"20","author":"A Carlsson","year":"1963","unstructured":"Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol. 1963;20:140\u20134. https:\/\/doi.org\/10.1111\/j.1600-0773.1963.tb01730.x.","journal-title":"Acta Pharmacol Toxicol"},{"key":"617_CR10","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1126\/science.3854","volume":"192","author":"I Creese","year":"1976","unstructured":"Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 1976;192:481\u20133. https:\/\/doi.org\/10.1126\/science.3854.","journal-title":"Science"},{"key":"617_CR11","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.181.4095.124","volume":"181","author":"GE Crane","year":"1973","unstructured":"Crane GE. Clinical psychopharmacology in its 20th year. Science. 1973;181:124\u20138. https:\/\/doi.org\/10.1126\/science.181.4095.124.","journal-title":"Science"},{"key":"617_CR12","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","volume":"45","author":"J Kane","year":"1988","unstructured":"Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789\u201396. https:\/\/doi.org\/10.1001\/archpsyc.1988.01800330013001.","journal-title":"Arch Gen Psychiatry"},{"key":"617_CR13","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1176\/ajp.151.6.825","volume":"151","author":"SR Marder","year":"1994","unstructured":"Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994;151:825\u201335. https:\/\/doi.org\/10.1176\/ajp.151.6.825.","journal-title":"Am J Psychiatry"},{"key":"617_CR14","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/s0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, \u00d6rey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951\u201362. https:\/\/doi.org\/10.1016\/s0140-6736(13)60733-3.","journal-title":"Lancet"},{"key":"617_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-25761-2_7","author":"FM Leweke","year":"2012","unstructured":"Leweke FM, Odorfer TM, Bumb JM. Medical needs in the treatment of psychotic disorders. Handb Exp Pharmacol. 2012. https:\/\/doi.org\/10.1007\/978-3-642-25761-2_7.","journal-title":"Handb Exp Pharmacol"},{"key":"617_CR16","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.schres.2008.09.025","volume":"110","author":"B Parsons","year":"2009","unstructured":"Parsons B, Allison DB, Loebel A, Williams K, Giller E, Romano S, et al. Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res. 2009;110:103\u201310. https:\/\/doi.org\/10.1016\/j.schres.2008.09.025.","journal-title":"Schizophr Res"},{"key":"617_CR17","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/s0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951\u201362. https:\/\/doi.org\/10.1016\/s0140-6736(13)60733-3.","journal-title":"Lancet"},{"key":"617_CR18","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1093\/schbul\/sby095","volume":"45","author":"MT Samara","year":"2019","unstructured":"Samara MT, Nikolakopoulou A, Salanti G, Leucht S. How many patients with schizophrenia do not respond to antipsychotic drugs in the short term? An analysis based on individual patient data from randomized controlled trials. Schizophr Bull. 2019;45:639\u201346. https:\/\/doi.org\/10.1093\/schbul\/sby095.","journal-title":"Schizophr Bull"},{"key":"617_CR19","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1176\/appi.ajp.20240076","volume":"182","author":"WP Horan","year":"2025","unstructured":"Horan WP, Sauder C, Harvey PD, Ramsay IS, Yohn SE, Keefe RSE, et al. The impact of xanomeline and trospium chloride on cognitive impairment in acute schizophrenia: replication in pooled data from two phase 3 trials. Am J Psychiatry. 2025;182:297\u2013306. https:\/\/doi.org\/10.1176\/appi.ajp.20240076.","journal-title":"Am J Psychiatry"},{"key":"617_CR20","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/nejmoa2017015","volume":"384","author":"SK Brannan","year":"2021","unstructured":"Brannan SK, Sawchak S, Miller AC, Lieberman JA, Paul SM, Breier A. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Engl J Med. 2021;384:717\u201326. https:\/\/doi.org\/10.1056\/nejmoa2017015.","journal-title":"N Engl J Med"},{"key":"617_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41386-023-01690-5","volume":"49","author":"SM Paul","year":"2024","unstructured":"Paul SM, Potter WZ. Finding new and better treatments for psychiatric disorders. Neuropsychopharmacology. 2024;49:3\u20139. https:\/\/doi.org\/10.1038\/s41386-023-01690-5.","journal-title":"Neuropsychopharmacology"},{"key":"617_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.schres.2023.11.015","volume":"264","author":"R Tandon","year":"2024","unstructured":"Tandon R, Nasrallah H, Akbarian S, Carpenter WT, DeLisi LE, Gaebel W, et al. The schizophrenia syndrome, circa 2024: what we know and how that informs its nature. Schizophr Res. 2024;264:1\u201328. https:\/\/doi.org\/10.1016\/j.schres.2023.11.015.","journal-title":"Schizophr Res"},{"key":"617_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/genes12121850","volume":"12","author":"MH Wahbeh","year":"2021","unstructured":"Wahbeh MH, Avramopoulos D. Gene-environment interactions in schizophrenia: a literature review. Genes (Basel). 2021;12:1850. https:\/\/doi.org\/10.3390\/genes12121850.","journal-title":"Genes (Basel)"},{"key":"617_CR24","doi-asserted-by":"publisher","unstructured":"European Network of National Networks studying Gene-Environment Interactions in Schizophrenia (EU-GEI) van Os J , Rutten BP, Myin-Germeys I, Delespaul P, Viechtbauer W, et al. Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations. Schizophr Bull. 2014;40:729\u201336. https:\/\/doi.org\/10.1093\/schbul\/sbu069.","DOI":"10.1093\/schbul\/sbu069"},{"key":"617_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.686666","volume":"12","author":"N Robinson","year":"2021","unstructured":"Robinson N, Bergen SE. Environmental risk factors for schizophrenia and bipolar disorder and their relationship to genetic risk: current knowledge and future directions. Front Genet. 2021;12:686666. https:\/\/doi.org\/10.3389\/fgene.2021.686666.","journal-title":"Front Genet"},{"key":"617_CR26","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41398-022-01904-2","volume":"12","author":"DL Spark","year":"2022","unstructured":"Spark DL, Fornito A, Langmead CJ, Stewart GD. Beyond antipsychotics: a twenty-first century update for preclinical development of schizophrenia therapeutics. Transl Psychiatry. 2022;12:147. https:\/\/doi.org\/10.1038\/s41398-022-01904-2.","journal-title":"Transl Psychiatry"},{"key":"617_CR27","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/s2215-0366(25)00031-8","volume":"12","author":"RA McCutcheon","year":"2025","unstructured":"McCutcheon RA, Pillinger T, Varvari I, Halstead S, Ayinde OO, Crossley NA, et al. INTEGRATE: international guidelines for the algorithmic treatment of schizophrenia. Lancet Psychiatry. 2025;12:384\u201394. https:\/\/doi.org\/10.1016\/s2215-0366(25)00031-8.","journal-title":"Lancet Psychiatry"},{"key":"617_CR28","unstructured":"European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Guideline on clinical investigation of medicinal products, including depot preparations in the treatment of schizophrenia. 2012. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-medicinal-products-including-depot-preparations-treatment-schizophrenia-revision-1_en.pdf. Accessed 04 May 2026."},{"key":"617_CR29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41537-021-00192-x","volume":"8","author":"CU Correll","year":"2022","unstructured":"Correll CU, Martin A, Patel C, Benson C, Goulding R, Kern-Sliwa J, et al. Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics. Schizophrenia. 2022;8:5. https:\/\/doi.org\/10.1038\/s41537-021-00192-x.","journal-title":"Schizophrenia"},{"key":"617_CR30","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.biopsych.2018.02.010","volume":"84","author":"LM Monteggia","year":"2018","unstructured":"Monteggia LM, Heimer H, Nestler EJ. Meeting report: can we make animal models of human mental illness? Biol Psychiatry. 2018;84:542\u20135. https:\/\/doi.org\/10.1016\/j.biopsych.2018.02.010.","journal-title":"Biol Psychiatry"},{"key":"617_CR31","doi-asserted-by":"publisher","unstructured":"Levy G. Integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. 1993. p. 7\u201313. https:\/\/doi.org\/10.1007\/978-1-4757-1520-0_2.","DOI":"10.1007\/978-1-4757-1520-0_2"},{"key":"617_CR32","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1093\/ijnp\/pyaa042","volume":"23","author":"TA Macek","year":"2020","unstructured":"Macek TA, Suzuki K, Asin K, Kimura H. Translational development strategies for TAK-063, a phosphodiesterase 10A inhibitor. Int J Neuropsychopharmacol. 2020;23:524\u201332. https:\/\/doi.org\/10.1093\/ijnp\/pyaa042.","journal-title":"Int J Neuropsychopharmacol"},{"key":"617_CR33","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.biopsych.2016.11.014","volume":"82","author":"D Bugarski-Kirola","year":"2017","unstructured":"Bugarski-Kirola D, Blaettler T, Arango C, Fleischhacker WW, Garibaldi G, Wang A, et al. Bitopertin in negative symptoms of schizophrenia\u2014results from the phase III flashlyte and daylyte studies. Biol Psychiatry. 2017;82:8\u201316. https:\/\/doi.org\/10.1016\/j.biopsych.2016.11.014.","journal-title":"Biol Psychiatry"},{"key":"617_CR34","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1111\/j.1365-2125.2012.04246.x","volume":"73","author":"AR Green","year":"2012","unstructured":"Green AR, Aronson JK. An agenda for UK clinical pharmacology: from basic to clinical neuropharmacology: targetophilia or pharmacodynamics? Br J Clin Pharmacol. 2012;73:959\u201367. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04246.x.","journal-title":"Br J Clin Pharmacol"},{"key":"617_CR35","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1111\/j.1476-5381.2011.01362.x","volume":"164","author":"JF Cryan","year":"2011","unstructured":"Cryan JF, Sweeney FF. The age of anxiety: role of animal models of anxiolytic action in drug discovery. Br J Pharmacol. 2011;164:1129\u201361. https:\/\/doi.org\/10.1111\/j.1476-5381.2011.01362.x.","journal-title":"Br J Pharmacol"},{"key":"617_CR36","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/nn.2647","volume":"13","author":"EJ Nestler","year":"2010","unstructured":"Nestler EJ, Hyman SE. Animal models of neuropsychiatric disorders. Nat Neurosci. 2010;13:1161\u20139. https:\/\/doi.org\/10.1038\/nn.2647.","journal-title":"Nat Neurosci"},{"key":"617_CR37","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/npp.2008.173","volume":"34","author":"A Markou","year":"2009","unstructured":"Markou A, Chiamulera C, Geyer MA, Tricklebank M, Steckler T. Removing obstacles in neuroscience drug discovery: the future path for animal models. Neuropsychopharmacology. 2009;34:74\u201389. https:\/\/doi.org\/10.1038\/npp.2008.173.","journal-title":"Neuropsychopharmacology"},{"key":"617_CR38","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1001\/archpsyc.1969.01740200112015","volume":"21","author":"WT McKinney","year":"1969","unstructured":"McKinney WT, Bunney WE. Animal model of depression: I. Review of evidence: implications for research. Arch Gen Psychiatry. 1969;21:240\u20138. https:\/\/doi.org\/10.1001\/archpsyc.1969.01740200112015.","journal-title":"Arch Gen Psychiatry"},{"key":"617_CR39","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/0278-5846(86)90051-5","volume":"10","author":"P Willner","year":"1986","unstructured":"Willner P. Validation criteria for animal models of human mental disorders: learned helplessness as a paradigm case. Prog Neuro-Psychopharmacol Biol Psychiatry. 1986;10:677\u201390. https:\/\/doi.org\/10.1016\/0278-5846(86)90051-5.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry."},{"key":"617_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF00427414","volume":"83","author":"P Willner","year":"1984","unstructured":"Willner P. The validity of animal models of depression. Psychopharmacology. 1984;83:1\u201316.","journal-title":"Psychopharmacology"},{"key":"617_CR41","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/s0893-133x(00)00137-8","volume":"23","author":"BK Lipska","year":"2000","unstructured":"Lipska BK, Weinberger DR. To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology. 2000;23:223\u201339. https:\/\/doi.org\/10.1016\/s0893-133x(00)00137-8.","journal-title":"Neuropsychopharmacology"},{"key":"617_CR42","doi-asserted-by":"crossref","unstructured":"Sarter M, Bruno JP. Animal Models in Biological Psychiatry. In: D'Haenen H, den Boer JA, Willner P, editors. Biol Psychiatry. Chichester, UK: John Wiley & Sons; 2002. p. 37\u201344.","DOI":"10.1002\/0470854871.chiii"},{"key":"617_CR43","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/2045-5380-1-9","volume":"1","author":"C Belzung","year":"2011","unstructured":"Belzung C, Lemoine M. Criteria of validity for animal models of psychiatric disorders: focus on anxiety disorders and depression. Biol Mood Anxiety Disord. 2011;1:9. https:\/\/doi.org\/10.1186\/2045-5380-1-9.","journal-title":"Biol Mood Anxiety Disord."},{"key":"617_CR44","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3371\/csrp.4.2.4","volume":"4","author":"C Wilson","year":"2010","unstructured":"Wilson C, Terry A. Neurodevelopmental animal models of schizophrenia: role in novel drug discovery and development. Clin Schizophr Relat Psychoses. 2010;4:124\u201337. https:\/\/doi.org\/10.3371\/csrp.4.2.4.","journal-title":"Clin Schizophr Relat Psychoses"},{"key":"617_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/bf00634146","volume":"50","author":"P Protais","year":"1976","unstructured":"Protais P, Costentin J, Schwartz JC. Climbing behavior induced by apomorphine in mice: a simple test for the study of dopamine receptors in striatum. Psychopharmacology. 1976;50:1\u20136. https:\/\/doi.org\/10.1007\/bf00634146.","journal-title":"Psychopharmacology"},{"key":"617_CR46","doi-asserted-by":"publisher","unstructured":"Peleg-Raibstein D, Feldon J, Meyer U. Current antipsychotics. Handb Exp Pharmacol. 2012. p. 361\u2013406. https:\/\/doi.org\/10.1007\/978-3-642-25761-2_14.","DOI":"10.1007\/978-3-642-25761-2_14"},{"key":"617_CR47","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.schres.2007.03.008","volume":"93","author":"DE Gard","year":"2007","unstructured":"Gard DE, Kring AM, Gard MG, Horan WP, Green MF. Anhedonia in schizophrenia: distinctions between anticipatory and consummatory pleasure. Schizophr Res. 2007;93:253\u201360. https:\/\/doi.org\/10.1016\/j.schres.2007.03.008.","journal-title":"Schizophr Res"},{"key":"617_CR48","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/bf00187257","volume":"93","author":"P Willner","year":"1987","unstructured":"Willner P, Towell A, Sampson D, Sophokleous S, Muscat R. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology. 1987;93:358\u201364. https:\/\/doi.org\/10.1007\/bf00187257.","journal-title":"Psychopharmacology"},{"key":"617_CR49","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1021\/acschemneuro.8b00553","volume":"10","author":"SE Yohn","year":"2019","unstructured":"Yohn SE, Conn PJ. Pick your model wisely: understanding the negative symptoms of schizophrenia in rodent models. ACS Chem Neurosci. 2019;10:33\u20135. https:\/\/doi.org\/10.1021\/acschemneuro.8b00553.","journal-title":"ACS Chem Neurosci"},{"key":"617_CR50","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/j.neubiorev.2012.04.006","volume":"37","author":"G Gilmour","year":"2013","unstructured":"Gilmour G, Arguello A, Bari A, Brown VJ, Carter C, Floresco SB, et al. Measuring the construct of executive control in schizophrenia: defining and validating translational animal paradigms for discovery research. Neurosci Biobehav Rev. 2013;37:2125\u201340. https:\/\/doi.org\/10.1016\/j.neubiorev.2012.04.006.","journal-title":"Neurosci Biobehav Rev"},{"key":"617_CR51","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1093\/schbul\/sbn157","volume":"35","author":"CS Carter","year":"2009","unstructured":"Carter CS, Barch DM, Gur R, Gur R, Pinkham A, Ochsner K. CNTRICS final task selection: social cognitive and affective neuroscience\u2013based measures. Schizophr Bull. 2009;35:153\u201362. https:\/\/doi.org\/10.1093\/schbul\/sbn157.","journal-title":"Schizophr Bull"},{"key":"617_CR52","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.biopsych.2006.09.042","volume":"62","author":"JA Waltz","year":"2007","unstructured":"Waltz JA, Frank MJ, Robinson BM, Gold JM. Selective reinforcement learning deficits in schizophrenia support predictions from computational models of striatal-cortical dysfunction. Biol Psychiatry. 2007;62:756\u201364. https:\/\/doi.org\/10.1016\/j.biopsych.2006.09.042.","journal-title":"Biol Psychiatry"},{"key":"617_CR53","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1093\/schbul\/sbu026","volume":"40","author":"DH Wolf","year":"2014","unstructured":"Wolf DH, Satterthwaite TD, Kantrowitz JJ, Katchmar N, Vandekar L, Elliott MA, et al. Amotivation in schizophrenia: integrated assessment with behavioral, clinical, and imaging measures. Schizophr Bull. 2014;40:1328\u201337. https:\/\/doi.org\/10.1093\/schbul\/sbu026.","journal-title":"Schizophr Bull"},{"key":"617_CR54","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.biopsych.2012.12.022","volume":"74","author":"JM Gold","year":"2013","unstructured":"Gold JM, Strauss GP, Waltz JA, Robinson BM, Brown JK, Frank MJ. Negative symptoms of schizophrenia are associated with abnormal effort-cost computations. Biol Psychiatry. 2013;74:130\u20136. https:\/\/doi.org\/10.1016\/j.biopsych.2012.12.022.","journal-title":"Biol Psychiatry"},{"key":"617_CR55","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1093\/schbul\/sbt236","volume":"40","author":"KM Gill","year":"2014","unstructured":"Gill KM, Cook JM, Poe MM, Grace AA. Prior antipsychotic drug treatment prevents response to novel antipsychotic agent in the methylazoxymethanol acetate model of schizophrenia. Schizophr Bull. 2014;40:341\u201350. https:\/\/doi.org\/10.1093\/schbul\/sbt236.","journal-title":"Schizophr Bull"},{"key":"617_CR56","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1001\/archpsyc.60.12.1228","volume":"60","author":"O Agid","year":"2003","unstructured":"Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry. 2003;60:1228\u201335. https:\/\/doi.org\/10.1001\/archpsyc.60.12.1228.","journal-title":"Arch Gen Psychiatry"},{"key":"617_CR57","doi-asserted-by":"crossref","unstructured":"Sarter M, Bruno JP. Animal Models in Biological Psychiatry. In: D'Haenen H, den Boer JA, Willner P, editors. Biol Psychiatry. Chichester, UK: John Wiley & Sons; 2002. p. 37\u201344.","DOI":"10.1002\/0470854871.chiii"},{"key":"617_CR58","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.pharmthera.2010.07.004","volume":"128","author":"JC Neill","year":"2010","unstructured":"Neill JC, Barnes S, Cook S, Grayson B, Idris NF, McLean SL, et al. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Ther. 2010;128:419\u201332. https:\/\/doi.org\/10.1016\/j.pharmthera.2010.07.004.","journal-title":"Pharmacol Ther"},{"key":"617_CR59","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.biopsych.2006.01.003","volume":"60","author":"H Moore","year":"2006","unstructured":"Moore H, Jentsch JD, Ghajarnia M, Geyer MA, Grace AA. A Neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia. Biol Psychiatry. 2006;60:253\u201364. https:\/\/doi.org\/10.1016\/j.biopsych.2006.01.003.","journal-title":"Biol Psychiatry"},{"key":"617_CR60","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1038\/npp.2011.76","volume":"36","author":"KM Gill","year":"2011","unstructured":"Gill KM, Lodge DJ, Cook JM, Aras S, Grace AA. A novel \u03b15GABAAR-positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia. Neuropsychopharmacology. 2011;36:1903\u201311. https:\/\/doi.org\/10.1038\/npp.2011.76.","journal-title":"Neuropsychopharmacology"},{"key":"617_CR61","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1176\/appi.ajp.2020.20030340","volume":"178","author":"NV Kraguljac","year":"2021","unstructured":"Kraguljac NV, McDonald WM, Widge AS, Rodriguez CI, Tohen M, Nemeroff CB. Neuroimaging biomarkers in schizophrenia. Am J Psychiatry. 2021;178:509\u201321. https:\/\/doi.org\/10.1176\/appi.ajp.2020.20030340.","journal-title":"Am J Psychiatry"},{"key":"617_CR62","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.neuron.2013.10.002","volume":"80","author":"G Buzs\u00e1ki","year":"2013","unstructured":"Buzs\u00e1ki G, Logothetis N, Singer W. Scaling brain size, keeping timing: evolutionary preservation of brain rhythms. Neuron. 2013;80:751\u201364. https:\/\/doi.org\/10.1016\/j.neuron.2013.10.002.","journal-title":"Neuron"},{"key":"617_CR63","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1177\/0269881114562093","volume":"29","author":"KG Phillips","year":"2015","unstructured":"Phillips KG, Uhlhaas PJ. Neural oscillations as a translational tool in schizophrenia research: rationale, paradigms and challenges. J Psychopharmacol. 2015;29:155\u201368. https:\/\/doi.org\/10.1177\/0269881114562093.","journal-title":"J Psychopharmacol"},{"key":"617_CR64","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1038\/s41386-020-0697-9","volume":"45","author":"DC Javitt","year":"2020","unstructured":"Javitt DC, Siegel SJ, Spencer KM, Mathalon DH, Hong LE, Martinez A, et al. A roadmap for development of neuro-oscillations as translational biomarkers for treatment development in neuropsychopharmacology. Neuropsychopharmacology. 2020;45:1411\u201322. https:\/\/doi.org\/10.1038\/s41386-020-0697-9.","journal-title":"Neuropsychopharmacology"},{"key":"617_CR65","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/oxfordjournals.schbul.a006887","volume":"27","author":"TM Maynard","year":"2001","unstructured":"Maynard TM, Sikich L, Lieberman JA, LaMantia A-S. Neural development, cell-cell signaling, and the \u201ctwo-hit\u201d hypothesis of schizophrenia. Schizophr Bull. 2001;27:457\u201376. https:\/\/doi.org\/10.1093\/oxfordjournals.schbul.a006887.","journal-title":"Schizophr Bull"},{"key":"617_CR66","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.neubiorev.2021.10.025","volume":"131","author":"CGJ Guerrin","year":"2021","unstructured":"Guerrin CGJ, Doorduin J, Sommer IE, de Vries EFJ. The dual hit hypothesis of schizophrenia: evidence from animal models. Neurosci Biobehav Rev. 2021;131:1150\u201368. https:\/\/doi.org\/10.1016\/j.neubiorev.2021.10.025.","journal-title":"Neurosci Biobehav Rev"},{"key":"617_CR67","doi-asserted-by":"publisher","first-page":"5968","DOI":"10.3390\/ijms23115968","volume":"23","author":"M Bia\u0142o\u0144","year":"2022","unstructured":"Bia\u0142o\u0144 M, W\u0105sik A. Advantages and limitations of animal schizophrenia models. Int J Mol Sci. 2022;23:5968. https:\/\/doi.org\/10.3390\/ijms23115968.","journal-title":"Int J Mol Sci"},{"key":"617_CR68","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1111\/j.1476-5381.2011.01386.x","volume":"164","author":"C Jones","year":"2011","unstructured":"Jones C, Watson D, Fone K. Animal models of schizophrenia. Br J Pharmacol. 2011;164:1162\u201394. https:\/\/doi.org\/10.1111\/j.1476-5381.2011.01386.x.","journal-title":"Br J Pharmacol"},{"key":"617_CR69","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/0706743718773728","volume":"64","author":"IR Winship","year":"2019","unstructured":"Winship IR, Dursun SM, Baker GB, Balista PA, Kandratavicius L, Maia-de-Oliveira JP, et al. An overview of animal models related to schizophrenia. Can J Psychiatry. 2019;64:5\u201317. https:\/\/doi.org\/10.1177\/0706743718773728.","journal-title":"Can J Psychiatry"},{"key":"617_CR70","unstructured":"Marcotte ER, Pearson DM, Srivastava LK. Animal models of schizophrenia: a critical review. J Psychiatry Neurosci. 2001;26:395\u2013410. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC167198\/pdf\/20011100s00005p395.pdf. Accessed 04 May 2026."},{"key":"617_CR71","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/s0006-8993(86)80193-7","volume":"396","author":"TE Robinson","year":"1986","unstructured":"Robinson TE, Becker JB. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res. 1986;396:157\u201398. https:\/\/doi.org\/10.1016\/s0006-8993(86)80193-7.","journal-title":"Brain Res"},{"key":"617_CR72","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1023\/a:1020214322065","volume":"32","author":"BA Ellenbroek","year":"2002","unstructured":"Ellenbroek BA, Cools AR. Apomorphine susceptibility and animal models for psychopathology: genes and environment. Behav Genet. 2002;32:349\u201361. https:\/\/doi.org\/10.1023\/a:1020214322065.","journal-title":"Behav Genet"},{"key":"617_CR73","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s002130050349","volume":"132","author":"F Sams-Dodd","year":"1997","unstructured":"Sams-Dodd F, Lipska BK, Weinberger DR. Neonatal lesions of the rat ventral hippocampus result in hyperlocomotion and deficits in social behaviour in adulthood. Psychopharmacology. 1997;132:303\u201310. https:\/\/doi.org\/10.1007\/s002130050349.","journal-title":"Psychopharmacology"},{"key":"617_CR74","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/s0893-133x(98)00004-9","volume":"19","author":"JD Jentsch","year":"1998","unstructured":"Jentsch JD, Taylor JR, Roth RH. Subchronic phencyclidine administration increases mesolimbic dopaminergic system responsivity and augments stress- and psychostimulant-induced hyperlocomotion. Neuropsychopharmacology. 1998;19:105\u201313. https:\/\/doi.org\/10.1016\/s0893-133x(98)00004-9.","journal-title":"Neuropsychopharmacology"},{"key":"617_CR75","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.tins.2018.12.004","volume":"42","author":"RA McCutcheon","year":"2019","unstructured":"McCutcheon RA, Abi-Dargham A, Howes OD. Schizophrenia, dopamine and the striatum: from biology to symptoms. Trends Neurosci. 2019;42:205\u201320. https:\/\/doi.org\/10.1016\/j.tins.2018.12.004.","journal-title":"Trends Neurosci"},{"key":"617_CR76","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/s0893-133x(98)00060-8","volume":"20","author":"JD Jentsch","year":"1999","unstructured":"Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 1999;20:201\u201325. https:\/\/doi.org\/10.1016\/s0893-133x(98)00060-8.","journal-title":"Neuropsychopharmacology"},{"key":"617_CR77","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1093\/cercor\/bhs322","volume":"24","author":"N Dawson","year":"2014","unstructured":"Dawson N, Xiao X, McDonald M, Higham DJ, Morris BJ, Pratt JA. Sustained NMDA receptor hypofunction induces compromised neural systems integration and schizophrenia-like alterations in functional brain networks. Cereb Cortex. 2014;24:452\u201364. https:\/\/doi.org\/10.1093\/cercor\/bhs322.","journal-title":"Cereb Cortex"},{"key":"617_CR78","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1038\/npp.2014.26","volume":"39","author":"N Dawson","year":"2014","unstructured":"Dawson N, McDonald M, Higham DJ, Morris BJ, Pratt JA. Subanesthetic ketamine treatment promotes abnormal interactions between neural subsystems and alters the properties of functional brain networks. Neuropsychopharmacology. 2014;39:1786\u201398. https:\/\/doi.org\/10.1038\/npp.2014.26.","journal-title":"Neuropsychopharmacology"},{"key":"617_CR79","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1021\/cn300138m","volume":"4","author":"JB Hanks","year":"2013","unstructured":"Hanks JB, Gonz\u00e1lez-Maeso J. Animal models of serotonergic psychedelics. ACS Chem Neurosci. 2013;4:33\u201342. https:\/\/doi.org\/10.1021\/cn300138m.","journal-title":"ACS Chem Neurosci"},{"key":"617_CR80","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/sj.npp.1300031","volume":"28","author":"SM Cochran","year":"2003","unstructured":"Cochran SM, Kennedy M, McKerchar CE, Steward LJ, Pratt JA, Morris BJ. Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs. Neuropsychopharmacology. 2003;28:265\u201375. https:\/\/doi.org\/10.1038\/sj.npp.1300031.","journal-title":"Neuropsychopharmacology"},{"key":"617_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2021.136354","volume":"770","author":"MA Sanavi","year":"2022","unstructured":"Sanavi MA, Ghazvini H, Zargari M, Ghalehnoei H, Hosseini-khah Z. Effects of clozapine and risperidone antipsychotic drugs on the expression of CACNA1C and behavioral changes in rat \u2018Ketamine model of schizophrenia. Neurosci Lett. 2022;770:136354. https:\/\/doi.org\/10.1016\/j.neulet.2021.136354.","journal-title":"Neurosci Lett"},{"key":"617_CR82","doi-asserted-by":"publisher","first-page":"274","DOI":"10.4088\/jcp.13078co7c","volume":"75","author":"A Abi-Dargham","year":"2014","unstructured":"Abi-Dargham A, Meyer JM. Schizophrenia: the role of dopamine and glutamate. J Clin Psychiatry. 2014;75:274\u20135. https:\/\/doi.org\/10.4088\/jcp.13078co7c.","journal-title":"J Clin Psychiatry"},{"key":"617_CR83","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1176\/ajp.153.4.466","volume":"153","author":"S Kapur","year":"1996","unstructured":"Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry. 1996;153:466\u201376. https:\/\/doi.org\/10.1176\/ajp.153.4.466.","journal-title":"Am J Psychiatry"},{"key":"617_CR84","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.coph.2014.01.001","volume":"14","author":"M Laruelle","year":"2014","unstructured":"Laruelle M. Schizophrenia: from dopaminergic to glutamatergic interventions. Curr Opin Pharmacol. 2014;14:97\u2013102. https:\/\/doi.org\/10.1016\/j.coph.2014.01.001.","journal-title":"Curr Opin Pharmacol"},{"key":"617_CR85","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1001\/archpsyc.1987.01800190080012","volume":"44","author":"DR Weinberger","year":"1987","unstructured":"Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry. 1987;44:660\u20139. https:\/\/doi.org\/10.1001\/archpsyc.1987.01800190080012.","journal-title":"Arch Gen Psychiatry"},{"key":"617_CR86","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1038\/mp.2012.23","volume":"17","author":"JL Rapoport","year":"2012","unstructured":"Rapoport JL, Giedd JN, Gogtay N. Neurodevelopmental model of schizophrenia: update 2012. Mol Psychiatry. 2012;17:1228\u201338. https:\/\/doi.org\/10.1038\/mp.2012.23.","journal-title":"Mol Psychiatry"},{"key":"617_CR87","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.bbr.2009.01.031","volume":"204","author":"DJ Lodge","year":"2009","unstructured":"Lodge DJ, Grace AA. Gestational methylazoxymethanol acetate administration: a developmental disruption model of schizophrenia. Behav Brain Res. 2009;204:306\u201312. https:\/\/doi.org\/10.1016\/j.bbr.2009.01.031.","journal-title":"Behav Brain Res"},{"key":"617_CR88","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.neubiorev.2009.05.001","volume":"33","author":"U Meyer","year":"2009","unstructured":"Meyer U, Feldon J, Fatemi SH. In-vivo rodent models for the experimental investigation of prenatal immune activation effects in neurodevelopmental brain disorders. Neurosci Biobehav Rev. 2009;33:1061\u201379. https:\/\/doi.org\/10.1016\/j.neubiorev.2009.05.001.","journal-title":"Neurosci Biobehav Rev"},{"key":"617_CR89","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/npp.1993.44","volume":"9","author":"BK Lipska","year":"1993","unstructured":"Lipska BK, Jaskiw GE, Weinberger DR. Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia. Neuropsychopharmacology. 1993;9:67\u201375. https:\/\/doi.org\/10.1038\/npp.1993.44.","journal-title":"Neuropsychopharmacology"},{"key":"617_CR90","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.bbr.2008.11.039","volume":"204","author":"KY Tseng","year":"2009","unstructured":"Tseng KY, Chambers RA, Lipska BK. The neonatal ventral hippocampal lesion as a heuristic neurodevelopmental model of schizophrenia. Behav Brain Res. 2009;204:295\u2013305. https:\/\/doi.org\/10.1016\/j.bbr.2008.11.039.","journal-title":"Behav Brain Res"},{"key":"617_CR91","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/mrdd.10004","volume":"8","author":"AS Brown","year":"2002","unstructured":"Brown AS, Susser ES. In utero infection and adult schizophrenia. Ment Retard Dev Disabil Res Rev. 2002;8:51\u20137. https:\/\/doi.org\/10.1002\/mrdd.10004.","journal-title":"Ment Retard Dev Disabil Res Rev"},{"key":"617_CR92","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1038\/sj.npp.1300248","volume":"28","author":"L Zuckerman","year":"2003","unstructured":"Zuckerman L, Rehavi M, Nachman R, Weiner I. Immune activation during pregnancy in rats leads to a postpubertal emergence of disrupted latent inhibition, dopaminergic hyperfunction, and altered limbic morphology in the offspring: a novel neurodevelopmental model of schizophrenia. Neuropsychopharmacology. 2003;28:1778\u201389. https:\/\/doi.org\/10.1038\/sj.npp.1300248.","journal-title":"Neuropsychopharmacology"},{"key":"617_CR93","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.pnpbp.2005.10.018","volume":"30","author":"ED Levin","year":"2006","unstructured":"Levin ED, Christopher NC. Effects of clozapine on memory function in the rat neonatal hippocampal lesion model of schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry. 2006;30:223\u20139. https:\/\/doi.org\/10.1016\/j.pnpbp.2005.10.018.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry."},{"key":"617_CR94","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/npp.1994.22","volume":"10","author":"BK Lipska","year":"1994","unstructured":"Lipska BK, Weinberger DR. Subchronic treatment with haloperidol and clozapine in rats with neonatal excitotoxic hippocampal damage. Neuropsychopharmacology. 1994;10:199\u2013205. https:\/\/doi.org\/10.1038\/npp.1994.22.","journal-title":"Neuropsychopharmacology"},{"key":"617_CR95","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1523\/jneurosci.5419-08.2009","volume":"29","author":"DJ Lodge","year":"2009","unstructured":"Lodge DJ, Behrens MM, Grace AA. A loss of parvalbumin-containing interneurons is associated with diminished oscillatory activity in an animal model of schizophrenia. J Neurosci. 2009;29:2344\u201354. https:\/\/doi.org\/10.1523\/jneurosci.5419-08.2009.","journal-title":"J Neurosci"},{"key":"617_CR96","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1038\/mp.2015.222","volume":"21","author":"S Canetta","year":"2016","unstructured":"Canetta S, Bolkan S, Padilla-Coreano N, Song LJ, Sahn R, Harrison NL, et al. Maternal immune activation leads to selective functional deficits in offspring parvalbumin interneurons. Mol Psychiatry. 2016;21:956\u201368. https:\/\/doi.org\/10.1038\/mp.2015.222.","journal-title":"Mol Psychiatry"},{"key":"617_CR97","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00702-022-02567-5","volume":"130","author":"A Schmitt","year":"2023","unstructured":"Schmitt A, Falkai P, Papiol S. Neurodevelopmental disturbances in schizophrenia: evidence from genetic and environmental factors. J Neural Transm. 2023;130:195\u2013205. https:\/\/doi.org\/10.1007\/s00702-022-02567-5.","journal-title":"J Neural Transm"},{"key":"617_CR98","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/wps.20629","volume":"18","author":"S Guloksuz","year":"2019","unstructured":"Guloksuz S, Pries L, Delespaul P, Kenis G, Luykx JJ, Lin BD, et al. Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: results from the EUGEI study. World Psychiatry. 2019;18:173\u201382. https:\/\/doi.org\/10.1002\/wps.20629.","journal-title":"World Psychiatry"},{"key":"617_CR99","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s11920-019-1091-3","volume":"21","author":"SA Stilo","year":"2019","unstructured":"Stilo SA, Murray RM. Non-genetic factors in schizophrenia. Curr Psychiat Rep. 2019;21:100. https:\/\/doi.org\/10.1007\/s11920-019-1091-3.","journal-title":"Curr Psychiat Rep."},{"key":"617_CR100","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1093\/schbul\/sby024","volume":"44","author":"N M\u00fcller","year":"2018","unstructured":"M\u00fcller N. Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations. Schizophr Bull. 2018;44:973\u201382. https:\/\/doi.org\/10.1093\/schbul\/sby024.","journal-title":"Schizophr Bull"},{"key":"617_CR101","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12745","volume":"25","author":"C Rohleder","year":"2020","unstructured":"Rohleder C, Pahlisch F, Graf R, Endepols H, Leweke FM. Different pharmaceutical preparations of \u03949-tetrahydrocannabinol differentially affect its behavioral effects in rats. Addict Biol. 2020;25:e12745. https:\/\/doi.org\/10.1111\/adb.12745.","journal-title":"Addict Biol"},{"key":"617_CR102","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/j.1369-1600.2008.00117.x","volume":"13","author":"M Schneider","year":"2008","unstructured":"Schneider M, Schomig E, Leweke FM. Acute and chronic cannabinoid treatment differentially affects recognition memory and social behavior in pubertal and adult rats. Addict Biol. 2008;13:345\u201357. https:\/\/doi.org\/10.1111\/j.1369-1600.2008.00117.x.","journal-title":"Addict Biol"},{"key":"617_CR103","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1017\/s1461145710000842","volume":"14","author":"FM Leweke","year":"2011","unstructured":"Leweke FM, Schneider M. Chronic pubertal cannabinoid treatment as a behavioural model for aspects of schizophrenia: effects of the atypical antipsychotic quetiapine. Int J Neuropsychoph. 2011;14:43\u201351. https:\/\/doi.org\/10.1017\/s1461145710000842.","journal-title":"Int J Neuropsychoph"},{"key":"617_CR104","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/0006-3223(93)90180-l","volume":"34","author":"MA Geyer","year":"1993","unstructured":"Geyer MA, Wilkinson LS, Humby T, Robbins TW. Isolation rearing of rats produces a deficit in prepulse inhibition of acoustic startle similar to that in schizophrenia. Biol Psychiat. 1993;34:361\u201372. https:\/\/doi.org\/10.1016\/0006-3223(93)90180-l.","journal-title":"Biol Psychiat"},{"key":"617_CR105","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s002130100800","volume":"156","author":"IC Weiss","year":"2001","unstructured":"Weiss IC, Feldon J. Environmental animal models for sensorimotor gating deficiencies in schizophrenia: a review. Psychopharmacology. 2001;156:305\u201326. https:\/\/doi.org\/10.1007\/s002130100800.","journal-title":"Psychopharmacology"},{"key":"617_CR106","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.schres.2019.01.030","volume":"213","author":"FV Gomes","year":"2019","unstructured":"Gomes FV, Zhu X, Grace AA. Stress during critical periods of development and risk for schizophrenia. Schizophr Res. 2019;213:107\u201313. https:\/\/doi.org\/10.1016\/j.schres.2019.01.030.","journal-title":"Schizophr Res"},{"key":"617_CR107","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-024-02668-5","author":"Z Li","year":"2024","unstructured":"Li Z, Mukherjee D, Duric B, Austin-Zimmerman I, Trotta G, Spinazzola E, et al. Systematic review and meta-analysis on the effects of chronic peri-adolescent cannabinoid exposure on schizophrenia-like behaviour in rodents. Mol Psychiatry. 2024. https:\/\/doi.org\/10.1038\/s41380-024-02668-5.","journal-title":"Mol Psychiatry"},{"key":"617_CR108","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1038\/s41380-019-0514-1","volume":"25","author":"FV Gomes","year":"2020","unstructured":"Gomes FV, Zhu X, Grace AA. The pathophysiological impact of stress on the dopamine system is dependent on the state of the critical period of vulnerability. Mol Psychiatry. 2020;25:3278\u201391. https:\/\/doi.org\/10.1038\/s41380-019-0514-1.","journal-title":"Mol Psychiatry"},{"key":"617_CR109","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1038\/sj.npp.1300225","volume":"28","author":"M Schneider","year":"2003","unstructured":"Schneider M, Koch M. Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacol. 2003;28:1760\u20139. https:\/\/doi.org\/10.1038\/sj.npp.1300225.","journal-title":"Neuropsychopharmacol"},{"key":"617_CR110","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1038\/sj.npp.1301664","volume":"33","author":"T Rubino","year":"2008","unstructured":"Rubino T, Vigano D, Realini N, Guidali C, Braida D, Capurro V, et al. Chronic delta 9-tetrahydrocannabinol during adolescence provokes sex-dependent changes in the emotional profile in adult rats: behavioral and biochemical correlates. Neuropsychopharmacology. 2008;33:2760\u201371. https:\/\/doi.org\/10.1038\/sj.npp.1301664.","journal-title":"Neuropsychopharmacology"},{"key":"617_CR111","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.biopsych.2005.01.026","volume":"57","author":"A Caspi","year":"2005","unstructured":"Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry. 2005;57:1117\u201327. https:\/\/doi.org\/10.1016\/j.biopsych.2005.01.026.","journal-title":"Biol Psychiatry"},{"key":"617_CR112","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/s0140-6736(07)61162-3","volume":"370","author":"TH Moore","year":"2007","unstructured":"Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370:319\u201328. https:\/\/doi.org\/10.1016\/s0140-6736(07)61162-3.","journal-title":"Lancet"},{"key":"617_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2023.105409","volume":"154","author":"C Mart\u00edn-Cuevas","year":"2023","unstructured":"Mart\u00edn-Cuevas C, Ramos-Herrero VD, Crespo-Facorro B, S\u00e1nchez-Hidalgo AC. Prenatal risk factors and postnatal cannabis exposure: assessing dual models of schizophrenia-like rodents. Neurosci Biobehav Rev. 2023;154:105409. https:\/\/doi.org\/10.1016\/j.neubiorev.2023.105409.","journal-title":"Neurosci Biobehav Rev"},{"key":"617_CR114","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1038\/sj.npp.1300634","volume":"30","author":"M Schneider","year":"2005","unstructured":"Schneider M, Koch M. Deficient social and play behavior in juvenile and adult rats after neonatal cortical lesion: effects of chronic pubertal cannabinoid treatment. Neuropsychopharmacology. 2005;30:944\u201357. https:\/\/doi.org\/10.1038\/sj.npp.1300634.","journal-title":"Neuropsychopharmacology"},{"key":"617_CR115","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/s41380-021-01420-7","volume":"27","author":"AK Merikangas","year":"2022","unstructured":"Merikangas AK, Shelly M, Knighton A, Kotler N, Tanenbaum N, Almasy L. What genes are differentially expressed in individuals with schizophrenia? A systematic review. Mol Psychiatry. 2022;27:1373\u201383. https:\/\/doi.org\/10.1038\/s41380-021-01420-7.","journal-title":"Mol Psychiatry"},{"key":"617_CR116","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1176\/appi.ajp.2019.18091085","volume":"176","author":"AB Zheutlin","year":"2019","unstructured":"Zheutlin AB, Dennis J, Linn\u00e9r RK, Moscati A, Restrepo N, Straub P, et al. Penetrance and pleiotropy of polygenic risk scores for schizophrenia in 106,160 patients across four health care systems. Am J Psychiatry. 2019;176:846\u201355. https:\/\/doi.org\/10.1176\/appi.ajp.2019.18091085.","journal-title":"Am J Psychiatry"},{"key":"617_CR117","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1093\/schbul\/sbs050","volume":"38","author":"F Varese","year":"2012","unstructured":"Varese F, Smeets F, Drukker M, Lieverse R, Lataster T, Viechtbauer W, et al. Childhood adversities increase the risk of psychosis: a meta-analysis of patient-control, prospective- and cross-sectional cohort studies. Schizophr Bull. 2012;38:661\u201371. https:\/\/doi.org\/10.1093\/schbul\/sbs050.","journal-title":"Schizophr Bull"},{"key":"617_CR118","doi-asserted-by":"publisher","unstructured":"Jaaro-Peled H. Chapter 9 Gene models of schizophrenia: DISC1 mouse models. Prog Brain Res. 2009;179:75\u201386. https:\/\/doi.org\/10.1016\/s0079-6123(09)17909-8.","DOI":"10.1016\/s0079-6123(09)17909-8"},{"key":"617_CR119","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.biopsych.2005.11.002","volume":"60","author":"PJ Harrison","year":"2006","unstructured":"Harrison PJ, Law AJ. Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol Psychiatry. 2006;60:132\u201340. https:\/\/doi.org\/10.1016\/j.biopsych.2005.11.002.","journal-title":"Biol Psychiatry"},{"key":"617_CR120","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.neulet.2007.05.019","volume":"421","author":"T Murotani","year":"2007","unstructured":"Murotani T, Ishizuka T, Hattori S, Hashimoto R, Matsuzaki S, Yamatodani A. High dopamine turnover in the brains of Sandy mice. Neurosci Lett. 2007;421:47\u201351. https:\/\/doi.org\/10.1016\/j.neulet.2007.05.019.","journal-title":"Neurosci Lett"},{"key":"617_CR121","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41586-022-04556-w","volume":"604","author":"T Singh","year":"2022","unstructured":"Singh T, Poterba T, Curtis D, Akil H, Eissa MA, Barchas JD, et al. Rare coding variants in ten genes confer substantial risk for schizophrenia. Nature. 2022;604:509\u201316. https:\/\/doi.org\/10.1038\/s41586-022-04556-w.","journal-title":"Nature"},{"key":"617_CR122","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-0723-z","volume":"10","author":"R Saito","year":"2020","unstructured":"Saito R, Koebis M, Nagai T, Shimizu K, Liao J, Wulaer B, et al. Comprehensive analysis of a novel mouse model of the 22q11.2 deletion syndrome: a model with the most common 3.0-Mb deletion at the human 22q11.2 locus. Transl Psychiatry. 2020;10:35. https:\/\/doi.org\/10.1038\/s41398-020-0723-z.","journal-title":"Transl Psychiatry"},{"key":"617_CR123","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108126","volume":"32","author":"K Nagahama","year":"2020","unstructured":"Nagahama K, Sakoori K, Watanabe T, Kishi Y, Kawaji K, Koebis M, et al. Setd1a insufficiency in mice attenuates excitatory synaptic function and recapitulates schizophrenia-related behavioral abnormalities. Cell Rep. 2020;32:108126. https:\/\/doi.org\/10.1016\/j.celrep.2020.108126.","journal-title":"Cell Rep"},{"key":"617_CR124","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/s0166-2236(00)01886-5","volume":"24","author":"RR Gainetdinov","year":"2001","unstructured":"Gainetdinov RR, Mohn AR, Caron MG. Genetic animal models: focus on schizophrenia. Trends Neurosci. 2001;24:527\u201333. https:\/\/doi.org\/10.1016\/s0166-2236(00)01886-5.","journal-title":"Trends Neurosci"},{"key":"617_CR125","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1073\/pnas.92.7.2785","volume":"92","author":"D Barbeau","year":"1995","unstructured":"Barbeau D, Liang JJ, Robitalille Y, Quirion R, Srivastava LK. Decreased expression of the embryonic form of the neural cell adhesion molecule in schizophrenic brains. Proc Natl Acad Sci. 1995;92:2785\u20139. https:\/\/doi.org\/10.1073\/pnas.92.7.2785.","journal-title":"Proc Natl Acad Sci"},{"key":"617_CR126","doi-asserted-by":"publisher","first-page":"7604","DOI":"10.1523\/jneurosci.15-11-07604.1995","volume":"15","author":"B Ellenbroek","year":"1995","unstructured":"Ellenbroek B, Geyer M, Cools A. The behavior of APO-SUS rats in animal models with construct validity for schizophrenia. J Neurosci. 1995;15:7604\u201311. https:\/\/doi.org\/10.1523\/jneurosci.15-11-07604.1995.","journal-title":"J Neurosci"},{"key":"617_CR127","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1038\/s41380-023-01949-9","volume":"28","author":"RA McCutcheon","year":"2023","unstructured":"McCutcheon RA, Keefe RSE, McGuire PK. Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment. Mol Psychiatry. 2023;28:1902\u201318. https:\/\/doi.org\/10.1038\/s41380-023-01949-9.","journal-title":"Mol Psychiatry"},{"key":"617_CR128","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","volume":"174","author":"OD Howes","year":"2017","unstructured":"Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJM, Birnbaum ML, et al. Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017;174:216\u201329. https:\/\/doi.org\/10.1176\/appi.ajp.2016.16050503.","journal-title":"Am J Psychiatry"},{"key":"617_CR129","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2021.13","volume":"64","author":"S Galderisi","year":"2021","unstructured":"Galderisi S, Kaiser S, Bitter I, Nordentoft M, Mucci A, Sab\u00e9 M, et al. EPA guidance on treatment of negative symptoms in schizophrenia. Eur Psychiatry. 2021;64:e21. https:\/\/doi.org\/10.1192\/j.eurpsy.2021.13.","journal-title":"Eur Psychiatry"},{"key":"617_CR130","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.biopsych.2022.01.004","volume":"92","author":"SD Sheridan","year":"2022","unstructured":"Sheridan SD, Horng JE, Perlis RH. Patient-derived in vitro models of microglial function and synaptic engulfment in schizophrenia. Biol Psychiatry. 2022;92:470\u20139. https:\/\/doi.org\/10.1016\/j.biopsych.2022.01.004.","journal-title":"Biol Psychiatry"},{"key":"617_CR131","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s13578-022-00928-x","volume":"12","author":"JM Nascimento","year":"2022","unstructured":"Nascimento JM, Saia-Cereda VM, Zuccoli GS, Reis-de-Oliveira G, Carregari VC, Smith BJ, et al. Proteomic signatures of schizophrenia-sourced iPSC-derived neural cells and brain organoids are similar to patients\u2019 postmortem brains. Cell Biosci. 2022;12:189. https:\/\/doi.org\/10.1186\/s13578-022-00928-x.","journal-title":"Cell Biosci"},{"key":"617_CR132","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/nature09915","volume":"473","author":"KJ Brennand","year":"2011","unstructured":"Brennand KJ, Simone A, Jou J, Gelboin-Burkhart C, Tran N, Sangar S, et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature. 2011;473:221\u20135. https:\/\/doi.org\/10.1038\/nature09915.","journal-title":"Nature"},{"key":"617_CR133","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1001\/jamapsychiatry.2020.0196","volume":"77","author":"A Kathuria","year":"2020","unstructured":"Kathuria A, Lopez-Lengowski K, Jagtap SS, McPhie D, Perlis RH, Cohen BM, et al. Transcriptomic landscape and functional characterization of induced pluripotent stem cell-derived cerebral organoids in schizophrenia. JAMA Psychiat. 2020;77:745\u201354. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.0196.","journal-title":"JAMA Psychiat"},{"key":"617_CR134","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1126\/science.aau5729","volume":"363","author":"SP Pa\u015fca","year":"2019","unstructured":"Pa\u015fca SP. Assembling human brain organoids. Science. 2019;363:126\u20137. https:\/\/doi.org\/10.1126\/science.aau5729.","journal-title":"Science"},{"key":"617_CR135","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/j.celrep.2015.07.061","volume":"12","author":"P Srikanth","year":"2015","unstructured":"Srikanth P, Han K, Callahan DG, Makovkina E, Muratore CR, Lalli MA, et al. Genomic DISC1 disruption in hiPSCs alters Wnt signaling and neural cell fate. Cell Rep. 2015;12:1414\u201329. https:\/\/doi.org\/10.1016\/j.celrep.2015.07.061.","journal-title":"Cell Rep"},{"key":"617_CR136","doi-asserted-by":"publisher","first-page":"13263","DOI":"10.1002\/jcp.27999","volume":"234","author":"RA Tahir","year":"2019","unstructured":"Tahir RA, Wu H, Javed N, Khalique A, Khan SAF, Mir A, et al. Pharmacoinformatics and molecular docking reveal potential drug candidates against Schizophrenia to target TAAR6. J Cell Physiol. 2019;234:13263\u201376. https:\/\/doi.org\/10.1002\/jcp.27999.","journal-title":"J Cell Physiol"},{"key":"617_CR137","doi-asserted-by":"publisher","first-page":"14748","DOI":"10.1021\/acsomega.0c05984","volume":"6","author":"M Mejia-Gutierrez","year":"2021","unstructured":"Mejia-Gutierrez M, V\u00e1squez-Paz BD, Fierro L, Maza JR. In silico repositioning of dopamine modulators with possible application to schizophrenia: pharmacophore mapping, molecular docking and molecular dynamics analysis. ACS Omega. 2021;6:14748\u201364. https:\/\/doi.org\/10.1021\/acsomega.0c05984.","journal-title":"ACS Omega"},{"key":"617_CR138","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1021\/ci400460q","volume":"54","author":"M Luo","year":"2014","unstructured":"Luo M, Wang XS, Roth BL, Golbraikh A, Tropsha A. Application of quantitative structure-activity relationship models of 5-HT1A receptor binding to virtual screening identifies novel and potent 5-HT1A ligands. J Chem Inf Model. 2014;54:634\u201347. https:\/\/doi.org\/10.1021\/ci400460q.","journal-title":"J Chem Inf Model"},{"key":"617_CR139","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41380-021-01201-2","volume":"27","author":"F Guan","year":"2022","unstructured":"Guan F, Ni T, Zhu W, Williams LK, Cui L-B, Li M, et al. Integrative omics of schizophrenia: from genetic determinants to clinical classification and risk prediction. Mol Psychiatry. 2022;27:113\u201326. https:\/\/doi.org\/10.1038\/s41380-021-01201-2.","journal-title":"Mol Psychiatry"},{"key":"617_CR140","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/nn.4238","volume":"19","author":"QJM Huys","year":"2016","unstructured":"Huys QJM, Maia TV, Frank MJ. Computational psychiatry as a bridge from neuroscience to clinical applications. Nat Neurosci. 2016;19:404\u201313. https:\/\/doi.org\/10.1038\/nn.4238.","journal-title":"Nat Neurosci"},{"key":"617_CR141","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.biopsych.2018.05.015","volume":"84","author":"P Sterzer","year":"2018","unstructured":"Sterzer P, Adams RA, Fletcher P, Frith C, Lawrie SM, Muckli L, et al. The predictive coding account of psychosis. Biol Psychiatry. 2018;84:634\u201343. https:\/\/doi.org\/10.1016\/j.biopsych.2018.05.015.","journal-title":"Biol Psychiatry"},{"key":"617_CR142","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/mp.2014.66","volume":"20","author":"RS Kahn","year":"2015","unstructured":"Kahn RS, Sommer IE. The neurobiology and treatment of first-episode schizophrenia. Mol Psychiatry. 2015;20:84\u201397. https:\/\/doi.org\/10.1038\/mp.2014.66.","journal-title":"Mol Psychiatry"},{"key":"617_CR143","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1038\/mp.2015.90","volume":"21","author":"SG Fillman","year":"2016","unstructured":"Fillman SG, Weickert TW, Lenroot RK, Catts SV, Bruggemann JM, Catts VS, et al. Elevated peripheral cytokines characterize a subgroup of people with schizophrenia displaying poor verbal fluency and reduced Broca\u2019s area volume. Mol Psychiatry. 2016;21:1090\u20138. https:\/\/doi.org\/10.1038\/mp.2015.90.","journal-title":"Mol Psychiatry"},{"key":"617_CR144","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.bbi.2022.06.012","volume":"105","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Owens SJ, Murphy CE, Ajulu K, Rothmond D, Purves-Tyson T, et al. Inflammation-related transcripts define \u201chigh\u201d and \u201clow\u201d subgroups of individuals with schizophrenia and bipolar disorder in the midbrain. Brain Behav Immun. 2022;105:149\u201359. https:\/\/doi.org\/10.1016\/j.bbi.2022.06.012.","journal-title":"Brain Behav Immun"},{"key":"617_CR145","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1176\/appi.ajp.2012.12010144","volume":"169","author":"A Demjaha","year":"2012","unstructured":"Demjaha A, Murray RM, McGuire PK, Kapur S, Howes OD. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry. 2012;169:1203\u201310. https:\/\/doi.org\/10.1176\/appi.ajp.2012.12010144.","journal-title":"Am J Psychiatry"},{"key":"617_CR146","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1176\/appi.ajp.2010.09091379","volume":"167","author":"T Insel","year":"2010","unstructured":"Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010;167:748\u201351. https:\/\/doi.org\/10.1176\/appi.ajp.2010.09091379.","journal-title":"Am J Psychiatry"},{"key":"617_CR147","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-126","volume":"11","author":"BN Cuthbert","year":"2013","unstructured":"Cuthbert BN, Insel TR. Toward the future of psychiatric diagnosis: the seven pillars of RDoC. BMC Med. 2013;11:126. https:\/\/doi.org\/10.1186\/1741-7015-11-126.","journal-title":"BMC Med"},{"key":"617_CR148","doi-asserted-by":"publisher","DOI":"10.1089\/can.2021.0181","author":"TA Couttas","year":"2022","unstructured":"Couttas TA, Boost C, Pahlisch F, Sykorova EB, Leweke JE, Koethe D, et al. Simultaneous assessment of serum levels and pharmacologic effects of cannabinoids on endocannabinoids and N-acylethanolamines by liquid chromatography\u2013tandem mass spectrometry. Cannabis Cannabinoid Res. 2022. https:\/\/doi.org\/10.1089\/can.2021.0181.","journal-title":"Cannabis Cannabinoid Res"},{"key":"617_CR149","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.bbi.2023.10.012","volume":"115","author":"TW Weickert","year":"2024","unstructured":"Weickert TW, Jacomb I, Lenroot R, Lappin J, Weinberg D, Brooks WS, et al. Adjunctive canakinumab reduces peripheral inflammation markers and improves positive symptoms in people with schizophrenia and inflammation: a randomized control trial. Brain Behav Immun. 2024;115:191\u2013200. https:\/\/doi.org\/10.1016\/j.bbi.2023.10.012.","journal-title":"Brain Behav Immun"}],"container-title":["Pharmaceutical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-026-00617-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40290-026-00617-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-026-00617-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:22:52Z","timestamp":1788495772000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40290-026-00617-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":149,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["617"],"URL":"https:\/\/doi.org\/10.1007\/s40290-026-00617-x","relation":{},"ISSN":["1178-2595","1179-1993"],"issn-type":[{"value":"1178-2595","type":"print"},{"value":"1179-1993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"assertion":[{"value":"1 June 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F.M.L. is a shareholder of curantis UG (Ltd.). C.R. is a shareholder of lero bioscience UG (Ltd.). I.D.-B., F.M.L. and C.R. are full or part-time employees of Endosane\n                      \u00ae\n                      Pharmaceuticals GmbH. F.M.L. received an Investigator Initiated Trial Grant from Endosane\n                      \u00ae\n                      Pharmaceuticals GmbH. All authors declare that they have no conflicts of interest with the contents of this article and that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable; this article did not involve research on any human participants or animals.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable; no new human data were created or analyzed for this article.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable; this article does not present human data.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable; no new human or animal data were created or analyzed for this article.","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable; no data were analyzed using a code for this article.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors contributed to the manuscript conception and design. The first draft of the manuscript was written by I.D.-B., and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript and agree to be accountable for all aspects of the work.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}